Mucus models to evaluate nanomedicines for diffusion

Archive ouverte

Groo, Anne-Claire | Lagarce, Frédéric

Edité par CCSD ; Elsevier -

International audience.

In the fast-growing field of nanomedicine, mucus is often the first barrier encountered by drug products in the body, and can be the only barrier if it is not overcome by the drug delivery system. Thus, there is a need to design new nanomedicines that are able to diffuse easily across mucus to reach their pharmacological targets. In this design process, mucus diffusion studies are mandatory and have an important role in the selection of the best drug candidates. However, there is currently no standard procedure for diffusion studies across mucus. In this Foundation Review, we discuss the differences observed within mucus models and experimental protocols in diffusion studies, with an emphasis on nanomedicine diffusion.

Suggestions

Du même auteur

Relevant Physicochemical Methods to Functionalize, Purify, and Characterize Surface-Decorated Lipid-Based Nanocarriers

Archive ouverte | Guyon, Léna | CCSD

International audience

Understanding the adsorption of salmon calcitonin, antimicrobial peptide AP114 and polymyxin B onto lipid nanocapsules

Archive ouverte | Umerska, Anita | CCSD

International audience. The adsorption of therapeutic molecules, e.g., peptides, onto nanocarriers is influenced by the properties of the carrier, adsorbed molecule and continuous phase. Hence, through changes in th...

Reverse micelle-lipid nanocapsules: a novel strategy for drug delivery of the plectasin derivate AP138 antimicrobial peptide

Archive ouverte | Groo, Anne-Claire | CCSD

International audience. Introduction: Resistance to traditional antibiotics is an increasingly serious problem. Antimicrobial peptides (AMPs) have emerged as a new therapeutic class with great potential against infe...

Chargement des enrichissements...